Its called the "biotech 2 step" and is more common with pre-revenue bios than with Big Pharma. We just dont have the resources ($$ and otherwise) they do. But your right, it doesn't change the data, which is the most important aspect of playing in spec bios.
Market Data 
Markets 
AI
